At the end of any summer, we brace ourselves — for back to school, returning to work and even for Christmas plans.
However, this year, the reality bump is like no other.
As the COVID-19 pandemic continues to reverberate globally, there is no doubt that we must be ready to face a long road ahead, certainly beyond the end of this year.
The fact that a vaccine, alongside effective treatments, is our only true exit strategy remains unchanged. The speed and scale of vaccine development have been remarkable, but it is important to avoid false hope.
I am optimistic that we will soon see results from the first vaccines coming through late-stage clinical trials.
However, we must temper this optimism, this talk of the perfect vaccine “just around the corner” or the idea that it will be a complete and immediate solution.
Over the summer, the UK vaccine task force has done an impressive job of securing access to a broad portfolio of potential COVID-19 vaccines, but I worry that, beyond the task force, too much hype is being applied to the first vaccines and in some countries too much focus on a political agenda and domestic provision.
There should be no place for notions of vaccine nationalism, with nations posturing that “their” vaccine will cross the finish line first and be fully deployed by Christmas or for a political moment.
The “first” vaccine, or even the first generation of vaccines, will most likely not be perfect; we need to be pragmatic and transparent on that front. The reality is that with these vaccines, we will be taking small steps to return to a sense of normality.
Plenty is attached to the word vaccine. When we hear it, we think of one of the greatest advances in human health, one that eliminates smallpox and saves millions every year from polio and tetanus, from HPV and the flu.
However, the first generation of COVID-19 vaccines will probably be only partially effective.
They might not be completely effective in all ages or appropriate in all health systems. It is very possible that they might provide immunity only for a limited period, even as short as 12 to 18 months.
This might not be what we are used to from a vaccine, but there is no doubt that the first effective vaccines, even imperfect ones, can have a major impact and be a precious commodity.
Urgency must not be misunderstood; accelerating vaccine development must not mean compromising safety. Transparent, rigorous assessment by independent regulatory bodies without political interference is non-negotiable.
Trust is our most important tool in public health and we must do everything we can to avoid putting that in doubt. It cannot be bought on short-term promises.
Already, there are worrying signs of diminishing trust in potential COVID-19 vaccines.
Polls suggest that in countries with some of the highest global case numbers, such as the US, there could be low uptake of any COVID-19 vaccine, no matter how effective.
This must not become a polarized political issue; public health is too important.
Most importantly, fair access to any vaccine must be addressed. No matter where the first vaccines originate, they must initially reach priority groups worldwide, particularly frontline healthcare workers and the most vulnerable.
Global cooperation is key to advancing these vaccines and restarting the economy.
If large parts of the world remain shut down because of the selfish hoarding of initial supplies by richer nations, we all suffer for it.
However, it is not enough to simply promise support for fair, global allocation. More nations must act with urgency and buy into a collective and pooled approach to vaccine access, all governments being clear that they will buy doses only for the most at risk in their populations.
The US not joining the vital COVID-19 Vaccines Global Access Facility (COVAX), which aims to ensure equal access to affordable vaccines, is disappointing.
It is more imperative than ever that those in stronger positions, with considerable resources, lead by example in fair allocation.
The UK has maneuvered itself into such a leading position. It has options on a 340 million-dose stockpile, the highest access per capita of any country. Yet only 20 to 30 percent of the UK population will require access to a vaccine in the first few months.
The UK’s position could be even stronger through firm commitments to pooling surplus doses through COVAX.
The European Commission has also shown important leadership and has committed 400 million euros (US$470 million), but it too is in a strong position to do more.
Such enlightened global leadership is badly needed at this time of crisis.
As we move through autumn and winter, we will see an increase in community transmission. Without urgent action to stop the current increased community transmission among young adults leading to transmission in hospitals and in social care, and thereby severe illness and deaths in vulnerable people, we will be facing a chaotic stop-start winter for schools and businesses.
We have to do everything possible to avoid this.
The first vaccine might not be a magic bullet that sends us back to normal in a matter of months. However, by using doses wisely on the people who most need them — and doing this alongside truthful, considered public health messaging that does not deal in false expectations — we will be in a strong position to avoid a repeat of the start of this year.
Jeremy Farrar is director of the Wellcome Trust.
Taiwan is rapidly accelerating toward becoming a “super-aged society” — moving at one of the fastest rates globally — with the proportion of elderly people in the population sharply rising. While the demographic shift of “fewer births than deaths” is no longer an anomaly, the nation’s legal framework and social customs appear stuck in the last century. Without adjustments, incidents like last month’s viral kicking incident on the Taipei MRT involving a 73-year-old woman would continue to proliferate, sowing seeds of generational distrust and conflict. The Senior Citizens Welfare Act (老人福利法), originally enacted in 1980 and revised multiple times, positions older
The Chinese Nationalist Party (KMT) has its chairperson election tomorrow. Although the party has long positioned itself as “China friendly,” the election is overshadowed by “an overwhelming wave of Chinese intervention.” The six candidates vying for the chair are former Taipei mayor Hau Lung-bin (郝龍斌), former lawmaker Cheng Li-wen (鄭麗文), Legislator Luo Chih-chiang (羅智強), Sun Yat-sen School president Chang Ya-chung (張亞中), former National Assembly representative Tsai Chih-hong (蔡志弘) and former Changhua County comissioner Zhuo Bo-yuan (卓伯源). While Cheng and Hau are front-runners in different surveys, Hau has complained of an online defamation campaign against him coming from accounts with foreign IP addresses,
Taiwan’s business-friendly environment and science parks designed to foster technology industries are the key elements of the nation’s winning chip formula, inspiring the US and other countries to try to replicate it. Representatives from US business groups — such as the Greater Phoenix Economic Council, and the Arizona-Taiwan Trade and Investment Office — in July visited the Hsinchu Science Park (新竹科學園區), home to Taiwan Semiconductor Manufacturing Co’s (TSMC) headquarters and its first fab. They showed great interest in creating similar science parks, with aims to build an extensive semiconductor chain suitable for the US, with chip designing, packaging and manufacturing. The
When Taiwan High Speed Rail Corp (THSRC) announced the implementation of a new “quiet carriage” policy across all train cars on Sept. 22, I — a classroom teacher who frequently takes the high-speed rail — was filled with anticipation. The days of passengers videoconferencing as if there were no one else on the train, playing videos at full volume or speaking loudly without regard for others finally seemed numbered. However, this battle for silence was lost after less than one month. Faced with emotional guilt from infants and anxious parents, THSRC caved and retreated. However, official high-speed rail data have long
RSS